IL37 and cancer: A study by Blauvelt et al. evaluated the cumulative safety experience with guselkumab, considering the incidence of adverse events such as cancer, using pooled data from phase-III VOYAGE 1 and 2 studies for up to 5 years, showing that the safety profile of this anti IL-23 drug remained constant and good over 5 years of continuous treatment [19].